Dyne Therapeutics Ownership | Who Owns Dyne Therapeutics?

Dyne Therapeutics Ownership Summary

Dyne Therapeutics is owned by 27.35% institutional investors, 0.69% insiders, and 71.96% retail investors. Blackrock is the largest institutional shareholder, holding 9.11% of DYN shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 2.35% of its assets in Dyne Therapeutics shares.

DYN Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Dyne Therapeutics	27.35%	0.69%	71.96%
Sector	Healthcare Stocks	279.42%	10.64%	-190.05%
Industry	Biotech Stocks	64.05%	10.69%	25.27%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock	7.39M	9.11%	$260.69M
Ra capital management	9.71M	8.84%	$101.61M
Atlas venture life science advisors	8.02M	7.95%	$188.94M
Fmr	8.00M	7.93%	$188.41M
Blackrock funding, inc. /de	7.95M	7.88%	$187.29M
Janus henderson group	7.38M	7.31%	$173.81M
Vanguard group	6.70M	6.65%	$157.94M
Fcpm iii services b.v.	5.46M	5.42%	$128.70M
State street	3.72M	3.68%	$87.58M
Braidwell lp	3.62M	3.29%	$37.88M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Atlas venture life science advisors	8.02M	23.05%	$188.94M
Fcpm iii services b.v.	5.46M	21.73%	$128.70M
Mpm asset management	682.38K	12.92%	$16.08M
Tcg crossover management	2.65M	6.10%	$62.44M
Vivo capital	1.11M	2.94%	$26.27M
Exome asset management	258.39K	2.40%	$2.70M
Vr adviser	2.17M	1.93%	$22.74M
Ra capital management	9.71M	1.70%	$101.61M
Siren	1.35M	1.40%	$31.75M
Artal group	1.52M	1.36%	$53.53M

Top Buyers

Holder	Shares	% Assets	Change
Ra capital management	9.71M	1.70%	3.33M
Braidwell lp	3.62M	1.33%	2.94M
Blackrock	7.39M	0.01%	2.00M
Vestal point capital, lp	1.80M	1.34%	1.80M
Perceptive advisors	2.31M	0.85%	1.77M

Top Sellers

Holder	Shares	% Assets	Change
Rtw investments, lp	1.69M	0.27%	-3.53M
Holocene advisors, lp	-	-	-2.35M
Adage capital partners gp	-	-	-1.95M
Jefferies financial group	-	-	-1.80M
Jennison associates	-	-	-1.21M

New Positions

Holder	Shares	% Assets	Change	Value
Vestal point capital, lp	1.80M	1.34%	1.80M	$18.83M
Frazier life sciences management	1.44M	0.69%	1.44M	$15.10M
Norges bank	950.10K	0.00%	950.10K	$22.38M
Ikarian capital	358.84K	0.46%	358.84K	$3.75M
Nantahala capital management	345.06K	0.14%	345.06K	$3.61M

Sold Out

Holder	Change
Headlands	-1.00
National bank of canada /fi/	-1.00
Farther finance advisors	-3.00
Ifp advisors	-3.00
Allworth financial lp	-5.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2025	25	-87.86%	30,059,507	-73.06%	27	0.22%	15	-85.98%	6	-90.32%
Dec 31, 2024	204	-1.45%	111,580,268	-0.38%	110	0.90%	105	-10.26%	62	14.81%
Sep 30, 2024	207	5.08%	111,994,758	0.90%	111	0.59%	117	-7.14%	54	17.39%
Jun 30, 2024	197	12.57%	110,993,406	16.43%	136	0.99%	126	-1.56%	46	58.62%
Mar 31, 2024	175	28.68%	95,333,552	36.34%	117	0.91%	128	85.51%	29	-27.50%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard US Total Market Shares ETF	2.65M	2.35%	2.40K
Vanguard Total Stock Mkt Idx Inv	3.08M	2.16%	-
Fidelity Growth Compy Commingled Pl O	1.79M	1.78%	348.61K
iShares Russell 2000 ETF	2.19M	1.54%	-41.69K
Janus Henderson Global Life Sciences	1.89M	1.33%	124.72K
Fidelity Growth Compy Commingled Pl S	1.84M	1.29%	-831.00
Janus Henderson Global Life Sciences D	1.81M	1.27%	-5.14K
T. Rowe Price New Horizons	1.12M	1.10%	-5.57K
US Small-Cap Growth II Equity Comp	1.12M	1.10%	219.42K
Janus Global Life Science AUSD	1.55M	1.09%	121.81K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jul 14, 2025	Cox John	CEO & President	Buy	$911.00K
Jun 05, 2025	Cox John	CEO & President	Sell	$54.20K
Jun 05, 2025	Kerr Douglas	Chief Medical Officer	Sell	$17.92K
Jun 05, 2025	Friedl-Naderer Johanna	Chief Commercial Officer	Sell	$1.95K
Mar 13, 2025	Friedl-Naderer Johanna	Chief Commercial Officer	Sell	$1.73K

Insider Transactions Trends

Date	Buy	Sell
2025 Q3	1	-
2025 Q2	-	3
2025 Q1	-	9
2024 Q4	-	24
2024 Q3	2	79

DYN Ownership FAQ

Who Owns Dyne Therapeutics?

Dyne Therapeutics shareholders are primarily institutional investors at 27.35%, followed by 0.69% insiders and 71.96% retail investors. The average institutional ownership in Dyne Therapeutics's industry, Biotech Stocks , is 64.05%, which Dyne Therapeutics falls below.

Who owns the most shares of Dyne Therapeutics?

Dyne Therapeutics’s largest shareholders are Blackrock (7.39M shares, 9.11%), Ra capital management (9.71M shares, 8.84%), and Atlas venture life science advisors (8.02M shares, 7.95%). Together, they hold 25.90% of Dyne Therapeutics’s total shares outstanding.

Does Blackrock own Dyne Therapeutics?

Yes, BlackRock owns 9.11% of Dyne Therapeutics, totaling 7.39M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 260.69M$. In the last quarter, BlackRock increased its holdings by 2M shares, a 37.05% change.

Who is Dyne Therapeutics’s biggest shareholder by percentage of total assets invested?

Atlas venture life science advisors is Dyne Therapeutics’s biggest shareholder by percentage of total assets invested, with 23.05% of its assets in 8.02M Dyne Therapeutics shares, valued at 188.94M$.

Who is the top mutual fund holder of Dyne Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Dyne Therapeutics shares, with 2.35% of its total shares outstanding invested in 2.65M Dyne Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools